Page last updated: 2024-12-06

2,4,6-trihydroxybenzaldehyde

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,4,6-trihydroxybenzaldehyde: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID68099
CHEMBL ID2403487
CHEBI ID189728
SCHEMBL ID307321
MeSH IDM0529628

Synonyms (35)

Synonym
phloroglucinol aldehyde
487-70-7
benzaldehyde,4,6-trihydroxy-
nsc-38610
nsc38610
formylphloroglucinal
einecs 207-663-7
brn 2254429
nsc 38610
inchi=1/c7h6o4/c8-3-5-6(10)1-4(9)2-7(5)11/h1-3,9-11
benzaldehyde, 2,4,6-trihydroxy-
2,4,6-trihydroxybenzaldehyde
2,4,6-trihydroxybenzaldehyde, >=97%
phloroglucinaldehyde
phloroglucinolcarboxaldehyde
T1744
CHEBI:189728
i70c45kro9 ,
unii-i70c45kro9
A827604
FT-0609876
AKOS015899852
formylphloroglucinol
CHEMBL2403487
SCHEMBL307321
2,4,6-trihydroxy-benzaldehyde
mfcd00003329
DTXSID90197594
CS-W005130
GS-3678
wlh-113
SY047039
HY-W005130
EN300-177718
Z1255485214
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
carboxylic esterAn ester of a carboxylic acid, R(1)C(=O)OR(2), where R(1) = H or organyl and R(2) = organyl.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID1269394Inhibition of wild type amyloid beta (1 to 42) (unknown origin) aggregation at 50 uM by Thioflavin-T fluorescence assay2016Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2
Structural insights into mechanisms for inhibiting amyloid β42 aggregation by non-catechol-type flavonoids.
AID758943Binding affinity to human LXRalpha-LBD by surface plasmon resonance2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
Cyanidin, a natural flavonoid, is an agonistic ligand for liver X receptor alpha and beta and reduces cellular lipid accumulation in macrophages and hepatocytes.
AID758940Agonist activity at human LXRalpha-LBD assessed as recruitment of co-activator peptide after 2 hrs by TR-FRET assay2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
Cyanidin, a natural flavonoid, is an agonistic ligand for liver X receptor alpha and beta and reduces cellular lipid accumulation in macrophages and hepatocytes.
AID1152636Antioxidant activity assessed as hydroxyl radical scavenging activity at 5 uM after 1 hr by 2-Deoxy-D-ribose degradation assay in presence of FeCl3 and EDTA2014Bioorganic & medicinal chemistry letters, Jun-15, Volume: 24, Issue:12
Synthesis and radical scavenging activity of phenol-imidazole conjugates.
AID758944Binding affinity to human LXRbeta-LBD by surface plasmon resonance2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
Cyanidin, a natural flavonoid, is an agonistic ligand for liver X receptor alpha and beta and reduces cellular lipid accumulation in macrophages and hepatocytes.
AID1269387Drug level treated with kaempferol after 4 hrs by LC/Q Tof-MS/MS analysis2016Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2
Structural insights into mechanisms for inhibiting amyloid β42 aggregation by non-catechol-type flavonoids.
AID1269388Inhibition of nucleation phase of HFIP-treated 15N-labelled wild type Amyloid beta (1 to 42) (unknown origin) assessed as time required for nucleation at 50 uM by Thioflavin-T fluorescence assay in presence of fibril seed (Rvb = 1 to 4 hrs)2016Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2
Structural insights into mechanisms for inhibiting amyloid β42 aggregation by non-catechol-type flavonoids.
AID1152632Antioxidant activity assessed as DPPH free radical scavenging activity measured as remaining DPPH at 100 uM after 60 mins by spectrophotometric analysis relative to control2014Bioorganic & medicinal chemistry letters, Jun-15, Volume: 24, Issue:12
Synthesis and radical scavenging activity of phenol-imidazole conjugates.
AID1269372Binding affinity to HFIP-treated 15N-labelled wild type Amyloid beta (1 to 42) monomer (unknown origin) assessed as change in chemical shifts at 500 uM after 1 hr by NMR analysis2016Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2
Structural insights into mechanisms for inhibiting amyloid β42 aggregation by non-catechol-type flavonoids.
AID1152637Antioxidant activity assessed as hydroxyl radical scavenging activity at 5 uM after 1 hr by 2-Deoxy-D-ribose degradation assay in presence of FeCl32014Bioorganic & medicinal chemistry letters, Jun-15, Volume: 24, Issue:12
Synthesis and radical scavenging activity of phenol-imidazole conjugates.
AID758939Agonist activity at human LXRbeta-LBD assessed as recruitment of co-activator peptide after 2 hrs by TR-FRET assay2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
Cyanidin, a natural flavonoid, is an agonistic ligand for liver X receptor alpha and beta and reduces cellular lipid accumulation in macrophages and hepatocytes.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (7.14)29.6817
2010's13 (92.86)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.20 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index5.33 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (7.14%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]